<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743911</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE 0044.0.146.000-09</org_study_id>
    <secondary_id>[2009/53430-7]</secondary_id>
    <nct_id>NCT01743911</nct_id>
  </id_info>
  <brief_title>Tadalafil Effects in Left Ventricle Diastolic Dysfunction in Resistant Hypertensive Patients</brief_title>
  <official_title>Phosphodiesterase-5 Inhibitor (Tadalafil) Two Weeks Administration Period Effects in Left Ventricle Diastolic Dysfunction and BNP Levels in Resistant Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Left ventricle diastolic dysfunction (LVDD) is associated with resistant hypertension. In&#xD;
      addition, brain natriuretic peptide (BNP) levels are elevated when LVDD is present. It has&#xD;
      been shown that phosphodiesterase-5 (PDE5) inhibition improves left ventricle diastolic&#xD;
      function in hypertensive rats, despite any difference in blood pressure levels. Also, left&#xD;
      ventricle diastolic function enhancement reduces BNP concentration in hypertensive patients.&#xD;
      However, it is unknown if these effects exists in humans with resistant hypertension.&#xD;
      Therefore, this study was developed to evaluate if the use of a PDE5 inhibitor (tadalafil)&#xD;
      for 2 weeks improves LVDD and its effects in BNP levels in resistant hypertensive patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Resistant hypertensive patients have a high incidence of left ventricle diastolic dysfunction&#xD;
      (LVDD). Lowering blood pressure levels improves diastolic function, however, there is no&#xD;
      proved effective treatment specifically for this disease. Studies in hypertensive rats have&#xD;
      shown presence of phosphodiesterase-5 in cardiac cells and an improvement in left ventricle&#xD;
      diastolic function using a phosphodiesterase-5 (PDE5) inhibitor, the sildenafil. PDE5 has&#xD;
      also been demonstrated in human heart cells with cardiac disease. In addition, LVDD is&#xD;
      associated with high levels of brain natriuretic peptide (BNP), which reduces with diastolic&#xD;
      function improvement. Therefore, it is reasonable to suppose that PDE-5 inhibitor use in&#xD;
      humans with LVDD and resistant hypertension could improve diastolic function. Objective:&#xD;
      Evaluate the chronic effect of a PDE-5 inhibitor on LVDD and BNP levels in resistant&#xD;
      hypertensive patients. Casuistic and methods: 20 resistant hypertensive patients with LVDD&#xD;
      types I and II will be evaluated with echocardiography study, ambulatory blood pressure&#xD;
      monitoring (ABPM), office blood pressure measurements, endothelial function analysis using&#xD;
      the brachial artery flow mediation dilation technique (FMD) and BNP plasma levels. Then, the&#xD;
      subjects will receive oral placebo for 2 weeks. After this period, the same exams will be&#xD;
      repeated. Two weeks later, the protocol will be performed again to the same 20 patients,&#xD;
      using tadalafil (the longest half-life PDE-5 inhibitor) 20mg orally instead of the placebo.&#xD;
      Hypothesis: investigators hypothesize that the use of tadalafil will improve left ventricle&#xD;
      diastolic function with BNP reduced levels and this effect will be independent of blood&#xD;
      pressure decrease or endothelial function improvement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Left Ventricle Diastolic Dysfunction</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Outcome measurement assessed by Echocardiogram before and after a 2-week tadalafil administration period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in endothelial function</measure>
    <time_frame>baseline and 2 weeks</time_frame>
    <description>Outcome measure assessed by flow-mediated dilation before and after a 2-week tadalafil administration period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure levels</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Blood pressure measurements assessed before and after a 2-week tadalafil administration period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in B-type Natriuretic Peptide (BNP-32) levels</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Plasma brain natriuretic peptide (BNP-32)assessed before and after a 2-week tadalafil administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cyclic guanosine monophosphate (cGMP) levels</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Cyclic guanosine monophosphate (cGMP) levels assessed before and after a 2-week tadalafil administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in nitrite levels</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Nitrite levels assessed before and after a 2-week tadalafil administration period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: sugar pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tadalafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: tadalafil</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sugar pill</intervention_name>
    <description>Sugar pills: 20mg orally, once a day for 2 weeks</description>
    <arm_group_label>sugar pill</arm_group_label>
    <other_name>No brand name.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Tadalafil pills: 20mg orally, once a day for 2 weeks.</description>
    <arm_group_label>tadalafil</arm_group_label>
    <other_name>Cialis, Lilly, USA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  resistant hypertension (according to Resistant Hypertension - American Heart&#xD;
             Association Statement - 2008);&#xD;
&#xD;
          -  compliance with antihypertensive treatment;&#xD;
&#xD;
          -  age &gt;35 years;&#xD;
&#xD;
          -  left ventricle diastolic dysfunction types I and II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  valvulopathy&#xD;
&#xD;
          -  decompensated heart failure&#xD;
&#xD;
          -  important cardiac arrhythmias&#xD;
&#xD;
          -  nephropathy&#xD;
&#xD;
          -  hepatopathy&#xD;
&#xD;
          -  autoimmune disease&#xD;
&#xD;
          -  tabagism&#xD;
&#xD;
          -  decompensated diabetes&#xD;
&#xD;
          -  uncontrolled dislipidemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heitor Moreno-Junior, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medical Sciences - Unicamp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratory of Cardiovascular Pharmacology - FCM - Unicamp</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13083-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>November 30, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Heitor Moreno Junior</investigator_full_name>
    <investigator_title>MD, PhD.</investigator_title>
  </responsible_party>
  <keyword>Tadalafil</keyword>
  <keyword>Resistant Hypertension</keyword>
  <keyword>Left Ventricle Diastolic Dysfunction</keyword>
  <keyword>Brain natriuretic peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

